Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial experience with tisagenlecleucel in a real-world...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Pasquini, Marcelo C., Hu, Zhen-Huan, Curran, Kevin, Laetsch, Theodore, Locke, Frederick, Rouce, Rayne, Pulsipher, Michael A., Phillips, Christine L., Keating, Amy, Frigault, Matthew J., Salzberg, Dana, Jaglowski, Samantha, Sasine, Joshua P., Rosenthal, Joseph, Ghosh, Monalisa, Landsburg, Daniel, Margossian, Steven, Martin, Paul L., Kamdar, Manali K., Hematti, Peiman, Nikiforow, Sarah, Turtle, Cameron, Perales, Miguel-Angel, Steinert, Patricia, Horowitz, Mary M., Moskop, Amy, Pacaud, Lida, Yi, Lan, Chawla, Raghav, Bleickardt, Eric, Grupp, Stephan
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2020
Teme:
Immunobiology and Immunotherapy
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656920/
https://ncbi.nlm.nih.gov/pubmed/33147337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003092
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items